CA3235913A1 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof - Google Patents
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Download PDFInfo
- Publication number
- CA3235913A1 CA3235913A1 CA3235913A CA3235913A CA3235913A1 CA 3235913 A1 CA3235913 A1 CA 3235913A1 CA 3235913 A CA3235913 A CA 3235913A CA 3235913 A CA3235913 A CA 3235913A CA 3235913 A1 CA3235913 A1 CA 3235913A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- alkyl
- inhibitors
- compound
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263875P | 2021-11-10 | 2021-11-10 | |
| US63/263,875 | 2021-11-10 | ||
| PCT/US2022/049426 WO2023086399A1 (en) | 2021-11-10 | 2022-11-09 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235913A1 true CA3235913A1 (en) | 2023-05-19 |
Family
ID=85132852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235913A Pending CA3235913A1 (en) | 2021-11-10 | 2022-11-09 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12091426B2 (https=) |
| EP (1) | EP4430052A1 (https=) |
| JP (1) | JP2024543377A (https=) |
| KR (1) | KR20240101654A (https=) |
| CN (1) | CN118510786A (https=) |
| AR (1) | AR127625A1 (https=) |
| AU (1) | AU2022388571A1 (https=) |
| CA (1) | CA3235913A1 (https=) |
| IL (1) | IL312361A (https=) |
| MX (1) | MX2024005431A (https=) |
| TW (1) | TW202334170A (https=) |
| WO (1) | WO2023086399A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| WO2025029995A1 (en) * | 2023-08-01 | 2025-02-06 | Arvinas Operations, Inc. | Hpk1 targeting compounds and uses thereof |
| CN117126133A (zh) * | 2023-08-14 | 2023-11-28 | 中国海洋大学 | 一种化合物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201600373YA (en) | 2013-07-31 | 2016-02-26 | Gilead Sciences Inc | Syk inhibitors |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| JP7472103B2 (ja) | 2018-08-22 | 2024-04-22 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| WO2020092528A1 (en) * | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| JP7503851B2 (ja) | 2019-05-06 | 2024-06-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 |
| WO2021168197A1 (en) | 2020-02-19 | 2021-08-26 | Nurix Therapeutics, Inc. | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
| US11739101B2 (en) * | 2020-05-06 | 2023-08-29 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
-
2022
- 2022-11-09 AR ARP220103080A patent/AR127625A1/es unknown
- 2022-11-09 US US18/054,118 patent/US12091426B2/en active Active
- 2022-11-09 AU AU2022388571A patent/AU2022388571A1/en active Pending
- 2022-11-09 KR KR1020247019189A patent/KR20240101654A/ko active Pending
- 2022-11-09 JP JP2024527355A patent/JP2024543377A/ja active Pending
- 2022-11-09 CN CN202280087971.7A patent/CN118510786A/zh active Pending
- 2022-11-09 IL IL312361A patent/IL312361A/en unknown
- 2022-11-09 CA CA3235913A patent/CA3235913A1/en active Pending
- 2022-11-09 MX MX2024005431A patent/MX2024005431A/es unknown
- 2022-11-09 TW TW111142873A patent/TW202334170A/zh unknown
- 2022-11-09 WO PCT/US2022/049426 patent/WO2023086399A1/en not_active Ceased
- 2022-11-09 EP EP22850684.6A patent/EP4430052A1/en active Pending
-
2024
- 2024-08-07 US US18/797,148 patent/US20240400587A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024543377A (ja) | 2024-11-21 |
| KR20240101654A (ko) | 2024-07-02 |
| CN118510786A (zh) | 2024-08-16 |
| WO2023086399A1 (en) | 2023-05-19 |
| IL312361A (en) | 2024-06-01 |
| US20240018162A1 (en) | 2024-01-18 |
| MX2024005431A (es) | 2024-07-19 |
| AU2022388571A1 (en) | 2024-05-09 |
| US12091426B2 (en) | 2024-09-17 |
| TW202334170A (zh) | 2023-09-01 |
| US20240400587A1 (en) | 2024-12-05 |
| AR127625A1 (es) | 2024-02-14 |
| EP4430052A1 (en) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020368542B2 (en) | Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety | |
| AU2019262927B2 (en) | Pyridazinones as PARP7 inhibitors | |
| US11739101B2 (en) | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | |
| CA3214806A1 (en) | Modulators of bcl6 proteolysis and associated methods of use | |
| ES2536281T3 (es) | Antagonistas del receptor CXCR4 | |
| AU2010210019B2 (en) | Compounds and compositions as protein kinase inhibitors | |
| CA3235913A1 (en) | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | |
| EP4367118B1 (en) | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | |
| KR20200101956A (ko) | 6-아자인돌 화합물 | |
| JP2022531801A (ja) | フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法 | |
| KR20230117577A (ko) | Brm을 표적으로 하는 화합물 및 연관된 사용 방법 | |
| EP4342892A1 (en) | Bruton's tyrosine kinase and mutant degrader, composition and application thereof | |
| WO2025019585A1 (en) | Kinase inhibitors | |
| HK40121612A (en) | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | |
| HK40108095B (en) | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | |
| HK40108095A (en) | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | |
| CN120957981A (zh) | 基于2,4-二苯胺嘧啶的Aurora-A激酶选择性降解诱导化合物 | |
| HK40115438A (zh) | 造血祖细胞激酶的双功能降解剂及其治疗用途 | |
| CN121752567A (zh) | 用于抑制wee1 a激酶方法中的吡唑并嘧啶酮化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241106 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |